According to the ZhItong finance and economics app, Juzi Bio (02367) rose more than 3%, and as of press time, it rose 3.12% to HKD 41.90, with a turnover of HKD 60.6538 million.
According to the research report released by SWHY, as the quality-price ratio of Chinese products increases, affordable consumption is on the rise, and the penetration rate of the mass market is increasing, which is bullish for big single products with strong stickiness and diversified channel layout. The medical and beauty industry will continue to benefit from abundant products on the supply side, and the normalization of the industry will maintain healthy development. The bank pointed out that the restructuring of collagen protein track is hot, which will help the rapid development of the company's brand and category. It is expected that the revenue growth rate of Juzi Bio in 24H1 will be about 43%, and the profit growth rate will be close to 33%.
According to the research report released by Caitong Securities, maintaining the "shareholding" rating of Juzi Bio, under the background of the continuous improvement of the beauty business and the expected approval of the medical and beauty products, Juzi is expected to achieve a "double play" in the beauty and medical business, driving performance and valuation to rise simultaneously. It is expected that the revenue in 2024-2026 will be CNY 4.99/6.43/7.95 billion respectively, and the net income attributable to shareholders will be CNY 1.99/2.53/3.12 billion respectively, corresponding to PE 20/16/13 times.